0001171843-26-002595
SEC filingXORTX Therapeutics Inc. has regained compliance with Nasdaq's minimum bid price requirement of US$1.00 per share following a 1-for-5 reverse stock split on April 6, 2026.
XORTX Therapeutics Inc. successfully addressed its Nasdaq listing deficiency under Rule 5550(a)(2) by implementing a 1-for-5 reverse stock split effective April 6, 2026, which enabled its common shares to sustain a bid price of at least US$1.00 for the required 10 consecutive trading days, culminating on April 17, 2026. The compliance letter from Nasdaq's Listing Qualifications Department, dated April 20, 2026, confirms the cure of this issue, reducing immediate delisting risk and supporting continued access to U.S. capital markets. This development is significant for investor confidence in the company's governance and market presence across NASDAQ: XRTX, TSXV: XRTX, and Frankfurt: ANU exchanges.